Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature

BACKGROUND: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients. However, the majority of patients does not recur and might thus be overtreated...

Descripción completa

Detalles Bibliográficos
Autores principales: Knauer, M, Cardoso, F, Wesseling, J, Bedard, P L, Linn, S C, Rutgers, E J T, van 't Veer, L J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008599/
https://www.ncbi.nlm.nih.gov/pubmed/21081926
http://dx.doi.org/10.1038/sj.bjc.6605916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008599/
https://www.ncbi.nlm.nih.gov/pubmed/21081926
http://dx.doi.org/10.1038/sj.bjc.6605916

Ejemplares similares